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Abstract
Background: Pneumococcal infections are major causes of morbidity and mortality worldwide. We use routine
hospital admissions data and time-series modelling analysis to estimate the impact of the seven and thirteen valent
pneumococcal conjugate vaccines (PCV7 and PCV13) on hospital admissions due to pneumococcal disease in England.
Methods: Hospital admissions for pneumococcal meningitis, bacteraemia and pneumonia between January 1, 2003 and
December 31, 2015 were identified from the national Hospital Episode Statistics database for all age groups in England.
We model the impact of pneumococcal vaccination using interrupted time series analysis. Hospital admissions prior to
vaccine introduction were extrapolated to predict the expected number of admissions in the absence of pneumococcal
vaccines. Admissions avoided over time were estimated by comparing the fitted interrupted time series and the expected
model for no vaccination in a Bayesian framework.
Results: Overall, there were 43,531 (95% credible interval (CrI): 36486–51,346) fewer hospital admissions due to
bacteraemia, meningitis and pneumonia in England during the period from 2006 to 2015 than would have
been expected if pneumococcal vaccines had not been implemented, with the majority of hospital admissions avoided
due to pneumonia. Among young children reductions in meningitis were more common, while among adults reductions
in pneumonia admissions were relatively more important, with no evidence for reduced bacteraemia and meningitis
among older adults. We estimated that 981 (95% CrI: 391–2018), 749 (95% CrI: 295–1442) and 1464 (95% CrI: 793–2522)
bacteraemia, meningitis and pneumonia related hospital admissions, respectively, were averted in children < 2 years of
age.
Conclusions: Substantial reductions in hospital admissions for bacteraemia, meningitis and pneumonia in England were
estimated after the introduction of childhood vaccination, with indirect effects being responsible for most of the hospital
admissions avoided.
Keywords: Hospital admissions, Interrupted time series analysis, Pneumococcal conjugate vaccines, Pneumococcal
disease, Indirect effects
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Background
Pneumococcal infections are a major cause of long-term
morbidity and mortality [1–3]. The introduction of
childhood pneumococcal vaccination has resulted in sig-
nificant reductions in pneumococcal disease in both
vaccinated and unvaccinated individuals worldwide. Sur-
veillance programmes on pneumococcal disease have
shown that invasive pneumococcal disease due to sero-
types covered by the vaccine have continued to decline
following vaccine introduction [4–10]. However, the vac-
cine programme has also been associated with concomi-
tant increases in carriage and disease due to other
serotypes not contained in the vaccine [11–13]. There
are concerns that serotype replacement could erode the
benefits of the pneumococcal vaccine in the long term.
England and Wales introduced the seven-valent conju-
gate vaccine (PCV7; containing serotypes 4, 6B, 9 V, 14,
18C, 19F and 23F) in September 2006 as part of their
universal paediatric immunisation programme, using a
primary series of two doses at 2 and 4months and a
booster dose after the first birthday. During the first year
of the programme, a catch-up campaign targeting chil-
dren under 2 years was also implemented. In April 2010,
PCV7 was replaced by a thirteen-valent vaccine (PCV13;
containing the seven serotypes contained in PCV7 plus
additional six serotypes 1, 3, 5, 6A, 7F and 19A) in the
childhood vaccination programme. Vaccination coverage
for the primary series and booster dose has risen from
80 and 83% in the first year of vaccine introduction to
90 and 94% in 2015/16, respectively [11, 12, 14]. Adults
aged 65 years and at-risk groups aged 2 years or over are
typically given the polysaccharide pneumococcal vaccine
(PPV23; containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9 N,
9 V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F,
23F, and 33F). PPV23 immunisation in adults was intro-
duced in August 2003. During the first year, all people
≥80 years were eligible for a single dose and in April
2004 it was extended to cover people aged ≥75 years. In
April 2005, a universal PPV23 schedule for adults aged
≥65 years was introduced and coverage in this age group
has remained stable at around 70% since introduction
[15]. PCV is not available for adults in England and
Wales apart from the severely immunocompromised.
Although studies using laboratory-based surveillance
data have shown sustained decreases in invasive pneumo-
coccal disease for the whole population in England and
Wales since the introduction of childhood vaccination
programmes [11, 12], the use of microbiologically con-
firmed cases might under estimate the burden of disease
as they focus on invasive disease confirmed by culture
from sterile sites and not on culture negative pneumonia.
There is limited data on the impact of vaccination on
long-term trends in hospital admissions following vaccine
introduction for individual pneumococcal disease
infections [16, 17]. Improved knowledge of disease burden
is critical to inform future research and guide intervention
policy [18–20]. We assessed the impact of pneumococcal
vaccination on individual and composite pneumococcal
disease hospitalisation in England from 2003 to 2015
using interrupted time series analysis.
Methods
Datasets
Data was extracted from the Hospital Episode Statistics
(HES) database, which contains information on all acute
care hospitalisations in England. Datasets analysed com-
prised of all inpatient hospitalisations between January 1,
2003 and December 31, 2015. Cases were identified by
the presence of relevant diagnostic discharge codes (pri-
mary or secondary diagnosis) listed in the patient’s dis-
charge record. The discrete health states or medical
conditions associated with Streptococcus pneumoniae in-
fection identified were bacteraemia (International Classi-
fication of Diseases, 10th revision [ICD-10], code A403),
meningitis (G001) and pneumonia with or without a
positive culture from a sterile site (J13). Our data repre-
sents more severe cases of pneumococcal infections re-
quiring hospitalisation.
The number of inpatient hospitalisations attributed to
pneumococcal infections were aggregated by month and
stratified according to the following age groups: < 2
years, 2–4 years, 5–14 years, 15–44 years, 45–64 years,
and ≥ 65 years. Although all hospital episodes for each
patient were obtained, we only used the first admission
episode that was due to a pneumococcal infection for
each patient in any epidemiological year. The period
January 2003 to March 2007 was defined as the pre-
PCV7 period, April 2007 to October 2010 as the PCV7-
era or pre-PCV13 period and November 2010 onwards
as the post-PCV13 period. Data on mid-year and age-
specific national population estimates from 2003 to 2015
was obtained from the Office for National Statistics, the
national statistical institute of the United Kingdom.
Statistical analysis
For each disease category, we ran age-specific Poisson
regression models with and without vaccination on
monthly time series. We fitted segmented Poisson
models using a Bayesian framework. Uncertainty was
given by 95% credible intervals (CrIs) obtained using the
parameter posterior distributions. We compared the re-
gression models without the impact of vaccination with
those with the impact of vaccination (i.e., the interrupted
time series regression) to test whether there was a
change over time and step change of hospital admissions
after vaccine introduction (see Additional file 1). In the
interrupted time series model, we created an indicator
variable taking the value 1 for the PCV7 era and 0 for both
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the pre-PCV7 and the period after switching PCV7 with
PCV13. The second indicator variable captured the pre-
PCV13 and post-PCV13 periods. The expected trend in
the absence of any vaccination (the counterfactual) was
based on the pre-PCV7 data. Cases (hospital admissions)
averted over time were calculated by comparing the fitted
interrupted time series and the counterfactual model. We
used the results of these calculations to estimate cumula-
tive reductions in hospital admissions.
Our pre-vaccine data covers a short period, and we ex-
trapolated the pre-vaccine trend based on 3 years data out
for approximately 10 years. Because this might give unreli-
able estimates we tested the robustness of our analysis by
also fitting the counterfactual model taking up to April
2010 as baseline. We also fitted a series of regression
models changing the lag period before any PCV7-vaccine
impact is expected. We varied this period from January
2007 to October 2007. In addition, as well as considering
the two intervention schedules, PCV7 and PCV13,
separately, we also conducted analyses assuming that the
impact of PCV13 was similar to that of PCV7.
Results
During the years studied, January 1, 2003 to December
31, 2015, there were 60,989 cases of patients with a first
admission for any of the three pneumococcal diseases
studied, with 11,617 (19%), 6062 (10%), and 43,310
(71%) cases of bacteraemia, meningitis, and pneumonia,
respectively. Hospital admissions showed seasonal fluc-
tuations with peaks occurring in winter months.
Monthly hospitalisations for bacteraemia and meningitis
were lowest in children 2–14 years of age.
Interrupted time series analyses
In Table 1 and Figs. 1 and 2, we present observed and
model-predicted hospital admissions, and the number of
hospital admissions avoided by disease and age category.
Reductions in hospitalisations for all studied pneumo-
coccal diseases combined were observed in all age
groups. In children < 2 years, 2–4 years and 5–14 years,
the number of admissions averted during the study
period were 3001 (95% CrI: 1987–4314), 2026 (95% CrI:
972–3809) and 2302 (95% CrI: 1058–4509), respectively
(Table 1). The number of admissions averted for adults
15–44 years, 45–64 years and ≥ 65 years were 13,533
(95% CrI:9822–18,214), 13,719 (95% CrI: 9628–18,556)
and 14,909 (95% CrI: 10693–19,564), respectively.
When the analysis was stratified by disease, bacteraemia
hospital admissions averted in age groups < 2 years, 15–44
years and 45–64 years decreased over time after the intro-
duction of PCV7 (Table 1; Additional file 1: Figures. S1, S2
and S3 showing monthly trends, risk rate ratios and num-
ber of admissions averted, respectively). In these age
groups, the total number of admissions averted over the
study period were 981 (95% CrI: 391–2018), 1011 (95% CrI:
212–2374) and 2102 (95% CrI: 854–4232), respectively. In
other age groups, no significant changes were observed in
the number of hospital admissions due to bacteraemia.
A substantial number of meningitis-related hospital ad-
missions were averted in children < 15 years, although in
children 2–15 years significant reductions were only ob-
served after switching PCV7 with PCV13 vaccine. An esti-
mated total of 749 (95% CrI: 295–1442), 379 (95% CrI:
45–1526), 368 (95% CrI: 19–1492) and 560 (95% CrI: 12–
1625) admissions were averted in children < 2 years, 2–4
years, 5–14 years and young adults 15–45 years, respect-
ively (Table 1; Additional file 1: Figures S4, S5 and S6,
showing monthly trends, risk rate ratios and number of
admissions averted, respectively). There were no signifi-
cant changes in the number of meningitis-related hospital
admissions in older adults ≥45 years of age.
In all age groups, the number of pneumonia-related
hospital admissions averted was substantial and sustained
over time. (Table 1; Additional file 1: Figures S7, S8 and
S9 showing monthly trends, risk rate ratios and number of
admissions averted, respectively). These ranged from 1464
(95% CrI: 793–2522) in children < 2 years to 16,963 (95%
CrI: 12662–21,937) in adults ≥65 years of age.
Overall, there were 43,531 (95% CrI: 36486–51,346)
fewer hospital admissions in England when the three dis-
eases are combined over the period of study than would
have been expected if pneumococcal vaccines had not
been implemented (Table 1; Additional file 1: Figures S10,
S11 and S12 showing monthly trends, risk rate ratios and
number of admissions averted, respectively). The large
majority of these reductions (approximately 96%) were
due to pneumonia hospital admissions and most of these
reductions were in adult populations ≥15 years of age.
In a sensitivity analysis where we fitted the counterfac-
tual model taking up to October 2010 as the PCV7-era
and then switching off the impact of the vaccine, we could
still reproduce counterfactual trends for no vaccine (Add-
itional file 1: Figure S13). In addition, we observed consist-
ent results when we assumed a similar vaccine effect for
PCV7 and PCV13 (Additional file 1: Figure S14).
In Additional file 1: Figure S15 we present the effects
of variation in lag period before any vaccine effect is ex-
pected (from January 2007 to October 2007). The results
show that a longer delay to when the PCV7 effect is
modelled results in a diminished role of the vaccination
programmes. Overall, our results were robust to changes
in the lag period before any vaccine is expected to have
an impact, as demonstrated by the estimated risk ratios
over time presented in Additional file 1: Figure S16.
Discussion
In this study, we have assessed the impact of the intro-
duction of pneumococcal conjugate vaccines in England
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on hospital admissions due to bacteraemia, meningitis,
and pneumonia infections between January 2003 and
December 2015. Our estimates suggest that the child-
hood pneumococcal vaccination programme was associ-
ated with substantial reductions in pneumococcal
disease-related hospitalisations in all age groups, with in-
direct effects being responsible for most of the hospital
admissions avoided. When stratified by disease condi-
tion, we observed a clear impact of vaccines in young
children < 2 years for all pneumococcal infections. Non-
Table 1 Observed and estimated (in the presence and absence of vaccination) total number of hospital admissions and admissions
averted between 2003 and 2015, including 95% credible intervalsa
Bacteraemia Meningitis Pneumonia All diseases
Age group
< 2 years
Observed 1248 1818 1243 4309
ITSb 1248 (1180, 1318) 1818(1735, 1903) 1243(1176, 1314) 4308(4181, 4440)
Counterfactualc 2232 (1632, 3269) 2566(2103, 3265) 2707(2030, 3770) 7309(6276, 8629)
Admissions avertedd −981(− 2018, − 391) − 749 (− 1442, − 295) −1464(− 2522, − 793) −3001(− 4314, − 1987)
2–4 years
Observed 411 227 861 1499
ITS 411 (372, 452) 227(198, 257) 861(804, 920) 1499(1423, 1575)
Counterfactual 536 (322, 1078) 607(268, 1753) 2595(1542, 4740) 3525(2463, 5325)
Admissions averted −126(− 661, + 87) − 379(− 1526, − 45) − 1734(− 3871, − 692) −2026(− 3809, − 972)
5–14 years
Observed 290 279 796 1365
ITS 290 (257, 324) 279(248, 313) 795(741, 852) 1365(1294, 1439)
Counterfactual 703 (273, 2321) 647(295, 1778) 2407(1438, 4346) 3667(2414, 5884)
Admissions averted −413(− 2030, + 14) −368(− 1492, − 19) − 1611(− 3536, − 647) −2302(− 4509, − 1058)
15–44 years
Observed 1546 939 7481 9966
ITS 1545(1469, 1624) 939(880, 1000) 7480(7312, 7652) 9967(9772, 10,163)
Counterfactual 2557(1750, 3922) 1499(950, 2569) 20,285(16,507, 25,257) 23,497(19,788, 28,185)
Admissions averted −1011(− 2374, − 212) − 560(− 1625, − 12) −12,798(− 17,750, − 9020) −13,533(− 18,214, − 9822)
45–64 years
Observed 2620 1549 10,826 14,995
ITS 2619(2521, 2722) 1549(1473, 1626) 10,827(10,628, 11,031) 14,994(14,755, 15,236)
Counterfactual 4772(3458, 6866) 1995(1399, 2996) 22,598(18,790, 27,438) 28,712(24,596, 33,567)
Admissions averted −2102(− 4232, − 854) −448(− 1442, + 141) − 11,777(− 16,597, − 7979) − 13,719(− 18,556, − 9628)
≥ 65 years
Observed 5392 1199 21,781 6955
ITS 5392(5249, 5538) 1199(1133, 1267) 21,779(21,492, 22,070) 28,371(28,040, 28,708)
Counterfactual 4722 (3459, 6866) 1221(836, 1891) 38,751(34,403, 43,763) 43,284(39,036, 47,987)
Admissions averted + 20(− 1199, + 929) −21(− 684, + 359) − 16,963(− 21,937, − 12,662) −14,909(− 19,564, − 10,693)
All age groups
Observed 11,507 6011 42,988 60,506
ITS 11,506(11,298, 11,718) 6011(5862, 6165) 42,986(42,580, 43,393) 60,502(60,024, 60,979)
Counterfactual 15,080(13,171, 17,492) 8266(7123, 9697) 84,821(77,680, 92,722) 104,022(96921111847)
Admissions averted − 3571(− 5973, − 1682) − 2258(− 3667,-1122) −41,845(− 49,706,-34,692) −43,531(− 51,346,-36,486)
aFor each diagnosis, separate models were fitted by age group
bITS – interrupted time series - model the impact of vaccination
cCounterfactual – expected hospital admissions in the absence of vaccination
dAdmissions averted since April 2007
Shiri et al. BMC Infectious Diseases          (2019) 19:510 Page 4 of 8
significant reductions were observed for bacteraemia as-
sociated hospital admissions in children 2–4 years and
5–14 years of age. In the elderly ≥65 years of age, the
vaccine indirect impact was diminished - with a trend
towards an increase in bacteraemia hospitalisations. The
small number of admissions observed in this age group
might have limited our power to detect relatively small
changes in the number of hospital admissions.
There was a sustained and substantial reduction in the
number of hospital admissions due to meningitis in chil-
dren < 15 years of age and young adults 15–44 years of
age, whereas in older adults ≥65 years of age, there were
no significant changes in the number of meningitis-
related hospital admissions. These results are similar to
those found in an analysis of hospital admissions data
from 1999 to 2011 [21]. In children aged 2–4 years and 5–
14 years, the number of hospital admissions due to menin-
gitis did not change significantly after the introduction of
PCV7 into the childhood immunisation programme. Plots
of rate ratios over time before and after pneumococcal
vaccines show a pattern of decline after PCV7 was
replaced with PCV13 in 2010, similar to what has been
observed using laboratory-based surveillance data [22].
These results mirror laboratory-based surveillance data
from other settings where there was a marked decline in
pneumococcal meningitis among children < 2 years and
no significant change in older age groups [7, 23, 24].
Our results indicate that pneumococcal conjugate vac-
cines have prevented hospital admissions due to pneu-
monia, under which both invasive pneumococcal disease
and non-invasive disease were recorded, in all age
groups with 90% of reductions in individuals ≥15 years
of age occurring through herd immunity. A broadly
similar 90% reduction in pneumonia-related hospital ad-
missions was observed in adults in the United States
[25]. Despite these huge reductions, a substantial burden
of pneumonia remains, particularly in adult age groups.
It has been demonstrated that pneumococcal vaccines
have substantially reduced invasive pneumococcal dis-
ease in the whole population of England and Wales. Our
data extend these observations to show significant re-
ductions in hospital admissions in all age groups, as a
Fig. 1 Observed and fitted monthly trends in all pneumococcal disease -related hospitalisations between 2003 and 2015 by age category. Vertical
grey lines represent the months when PCV7 and PCV13 were introduced into the immunisation programme, respectively. Counterfactual – expected
hospital admissions in the absence of vaccination (blue lines). 95% credible intervals are given in light blue lines
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result of clinically-diagnosed pneumonia that comprised
the largest quantitative reduction in admissions. The
patterns of decline in all hospitalisations due to the com-
bined three pneumococcal diseases reflect those ob-
served from the surveillance data based on laboratory
confirmed IPD cases over the same period [11, 12, 14].
Including the latest data up to the epidemiological year
2016/17, Ladhani et al. estimated that paediatric vaccin-
ation approximately saved 40,000 cases of invasive
pneumococcal disease [12]. This number is lower, al-
though not significantly so, than our estimate of 43,531
(95% CrI: 36486–51,346), despite the surveillance data
having more data points from an extra year and more
data from Wales. Using HES data, we were able to con-
duct our estimation for individual disease outcomes, and
further include combined disease outcomes.
Our study, using available national hospital data, does
not cover recent years where preliminary laboratory sur-
veillance data suggests significant replacement disease
due to non-vaccine serotypes, particularly in adults. The
recent increase in replacement disease therefore
warrants further work using the methods we have used
here as sufficient later data becomes available. Previous
studies have shown an increase in admissions to hospital
for pneumococcal disease before the introduction of
pneumococcal vaccines [17, 21, 26]. In the Oxfordshire
region of England, community acquired pneumonia hos-
pitalisations from all causes have been increasing, with
no evidence that this increase is influenced by coding
practices or changes in population demographics [16].
The rise may be due to population factors, changes in
health care organisation, biologic processes or a combin-
ation of these factors [17]. Given this background, in the
absence of vaccines, hospitalisations due to pneumococ-
cal diseases studied here are expected to have increased,
as shown by our counterfactual trends.
Our study has several limitations. First, we did not have
serotype-specific data, so the analysis could not separate re-
ductions due to vaccine serotypes from non-vaccine sero-
type disease. Second, we have relied on administrative data
that is based on diagnostic codes, which we have assumed
were assigned correctly; this may not always be the case as
Fig. 2 Estimated monthly pneumococcal disease admissions averted due to the introduction of the vaccination programmes by age category.
Error bars represent the 95% credible intervals. Vertical lines represent the months when PCV7 and PCV13 were introduced into the immunisation
programme, respectively
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there may be miscoding. Third, we did not attempt to infer
the number of hospital admissions avoided due to the use of
PPV23 in adults. However, the greatest reduction in burden
was among adults under 65 years, rather than the age group
receiving PPV23 routinely, so that the effect of PPV23 may
have been small. Lastly, the interrupted time series used as-
sumes that the pre-vaccination trends are linear and con-
tinue to be linear in the post vaccine period, thus missing
unexpected effects that might affect the number of hospitali-
sations observed. We also did not have data on non-
pneumonia hospitalisations that could have been useful to
capture counterfactual trends in hospitalisations accurately.
Despite these limitations, our study covers the longest
observation period post vaccine introduction of any ana-
lysis examining the impact of pneumococcal vaccina-
tions on hospitalisation due to individual pneumococcal
diseases such as bacteraemia, meningitis and pneumonia
in England. Using ICD-coded data we have shown that
vaccines have reduced the burden of pneumococcal
disease-related hospital admissions in unvaccinated pop-
ulations, particularly in young adults, similar results to
those of laboratory-based surveillance. However, the bur-
den of meningitis and bacteraemia has not changed in
adults ≥65 years of age, despite this population receiving
PPV23 in addition to indirect effects generated by the
childhood programme. There may be utility in inferring
the population-based impact of pneumococcal vaccines
using health-care data in countries with little, or no
laboratory-based surveillance for pneumococcal disease,
including many low and middle-income countries.
Conclusions
This study provides additional observational evidence
about temporal trends in pneumococcal disease in Eng-
land before and after the introduction of paediatric
pneumococcal vaccinations. Our analysis has shown that
these vaccines have significantly reduced the burden of
pneumococcal disease related hospital admissions, in-
cluding both culture confirmed and culture negative
pneumonia, with indirect effects being responsible for
most of the hospital admissions avoided.
Additional file
Additional file 1: This supplementary file contains detailed statistical
approaches used to analyse the data, additional results for individual
disease conditions and sensitivity analysis exploring the impact of fitting
different counterfactual models and adjusting the time when vaccines’
effect is started in the time series analysis (DOCX 747 kb)
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